Effects of Prebiotics vs a Diet Low in FODMAPs in Patients With Functional Gut Disorders.
Study Goal
The researchers aimed to compare the effects of a prebiotic supplement plus a Mediterranean-type diet versus a placebo supplement plus a low-FODMAP diet on fecal microbiota composition, intestinal gas production, and digestive sensations in patients with functional gastrointestinal disorders.
Results Summary
The low-FODMAP diet led to a decrease in Bifidobacterium and an increase in Bilophila wadsworthia, with significant symptom reductions that persisted for 2 weeks post-intervention. However, symptoms reappeared immediately after discontinuing the diet, suggesting intermittent prebiotic administration might be an alternative.
Population
Patients with functional gastrointestinal disorders and flatulence.
Effective Dosage
Not specified for the low-FODMAP diet (only the prebiotic supplement dosage is mentioned).
Duration
4 weeks of intervention, followed by 2 weeks of follow-up.
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
prebiotic supplement (2.8 g/d Bimuno containing 1.37 g beta-galactooligosaccharide) plus a placebo (Mediterranean-type diet) | increase | abundance of Bifidobacterium sequences | patients with functional gastrointestinal disorders with flatulence | - | increase in the abundance of Bifidobacterium sequences | #1 |
diet low in FODMAP | decrease | abundance of Bifidobacterium sequences | patients with functional gastrointestinal disorders with flatulence | - | decrease in the abundance of Bifidobacterium sequences | #2 |
prebiotic supplement (2.8 g/d Bimuno containing 1.37 g beta-galactooligosaccharide) plus a placebo (Mediterranean-type diet) | decrease | abundance of Bilophila wadsworthia sequences | patients with functional gastrointestinal disorders with flatulence | - | decrease in the abundance of Bilophila wadsworthia sequences | #3 |
diet low in FODMAP | increase | abundance of Bilophila wadsworthia sequences | patients with functional gastrointestinal disorders with flatulence | - | increase in the abundance of Bilophila wadsworthia sequences | #4 |
prebiotic supplement (2.8 g/d Bimuno containing 1.37 g beta-galactooligosaccharide) plus a placebo (Mediterranean-type diet) | decrease | symptom scores | patients with functional gastrointestinal disorders with flatulence | - | reductions in all symptom scores | #5 |
prebiotic supplement (2.8 g/d Bimuno containing 1.37 g beta-galactooligosaccharide) plus a placebo (Mediterranean-type diet) | no change | flatulence | patients with functional gastrointestinal disorders with flatulence | - | reductions in flatulence were not significant | #6 |
prebiotic supplement (2.8 g/d Bimuno containing 1.37 g beta-galactooligosaccharide) plus a placebo (Mediterranean-type diet) | no change | borborygmi | patients with functional gastrointestinal disorders with flatulence | - | reductions in borborygmi were not significant | #7 |
diet low in FODMAP | decrease | symptom scores | patients with functional gastrointestinal disorders with flatulence | - | reductions in all symptom scores | #8 |
prebiotic supplementation | decrease | symptoms | patients with functional gastrointestinal disorders with flatulence | 2 weeks | decrease in symptoms persisted for 2 weeks after patients discontinued | #9 |
low-FODMAP diet | increase | symptoms | patients with functional gastrointestinal disorders with flatulence | immediately | symptoms reappeared immediately after patients discontinued | #10 |
Prebiotics and diets low in fermentable oligo-, di-, mono-saccharides and polyols (low-FODMAP diet) might reduce symptoms in patients with functional gastrointestinal disorders, despite reports that some nonabsorbable, fermentable meal products (prebiotics) provide substrates for colonic bacteria and thereby increase gas production. We performed a randomized, parallel, double-blind study of patients with functional gastrointestinal disorders with flatulence. We compared the effects of a prebiotic supplement (2.8 g/d Bimuno containing 1.37 g beta-galactooligosaccharide) plus a placebo (Mediterranean-type diet (prebiotic group, n = 19) vs a placebo supplement (2.8 g xylose) plus a diet low in FODMAP (low-FODMAP group, n = 21) for 4 weeks; patients were then followed for 2 weeks. The primary outcome was effects on composition of the fecal microbiota, analyzed by 16S sequencing. Secondary outcomes were intestinal gas production and digestive sensations. After 4 weeks, we observed opposite effects on microbiota in each group, particularly in relation to the abundance of Bifidobacterium sequences (increase in the prebiotic group and decrease in the low-FODMAP group; P = .042), and Bilophila wadsworthia (decrease in the prebiotic group and increase in the low-FODMAP group; P = .050). After 4 weeks, both groups had statistically significant reductions in all symptom scores, except reductions in flatulence and borborygmi were not significant in the prebiotic group. Although the decrease in symptoms persisted for 2 weeks after patients discontinued prebiotic supplementation, symptoms reappeared immediately after patients discontinued the low-FODMAP diet. Intermittent prebiotic administration might therefore be an alternative to dietary restrictions for patients with functional gut symptoms. ClinicalTrials.gov no.: NCT02210572.